393 related articles for article (PubMed ID: 19641500)
1. Mimicking the BH3 domain to kill cancer cells.
Ni Chonghaile T; Letai A
Oncogene; 2008 Dec; 27 Suppl 1(0 1):S149-57. PubMed ID: 19641500
[TBL] [Abstract][Full Text] [Related]
2. B cell lymphoma-2 (BCL-2) homology domain 3 (BH3) mimetics demonstrate differential activities dependent upon the functional repertoire of pro- and anti-apoptotic BCL-2 family proteins.
Renault TT; Elkholi R; Bharti A; Chipuk JE
J Biol Chem; 2014 Sep; 289(38):26481-26491. PubMed ID: 25096574
[TBL] [Abstract][Full Text] [Related]
3. Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: a breakthrough in anticancer therapy?
Labi V; Grespi F; Baumgartner F; Villunger A
Cell Death Differ; 2008 Jun; 15(6):977-87. PubMed ID: 18369371
[TBL] [Abstract][Full Text] [Related]
4. Small molecule inhibition of the Bcl-X(L)-BH3 protein-protein interaction: proof-of-concept of an in vivo chemopotentiator ABT-737.
Stauffer SR
Curr Top Med Chem; 2007; 7(10):961-5. PubMed ID: 17508927
[TBL] [Abstract][Full Text] [Related]
5. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy.
Kang MH; Reynolds CP
Clin Cancer Res; 2009 Feb; 15(4):1126-32. PubMed ID: 19228717
[TBL] [Abstract][Full Text] [Related]
6. BH3 mimetics to improve cancer therapy; mechanisms and examples.
Zhang L; Ming L; Yu J
Drug Resist Updat; 2007 Dec; 10(6):207-17. PubMed ID: 17921043
[TBL] [Abstract][Full Text] [Related]
7. Targeting ERK1/2-bim signaling cascades by BH3-mimetic ABT-737 as an alternative therapeutic strategy for oral cancer.
Shin JA; Kim LH; Lee SJ; Jeong JH; Jung JY; Lee HN; Hong IS; Cho SD
Oncotarget; 2015 Nov; 6(34):35667-83. PubMed ID: 26447615
[TBL] [Abstract][Full Text] [Related]
8. BH3 mimetics: status of the field and new developments.
Billard C
Mol Cancer Ther; 2013 Sep; 12(9):1691-700. PubMed ID: 23974697
[TBL] [Abstract][Full Text] [Related]
9. Current overview on the clinical update of Bcl-2 anti-apoptotic inhibitors for cancer therapy.
Suvarna V; Singh V; Murahari M
Eur J Pharmacol; 2019 Nov; 862():172655. PubMed ID: 31494078
[TBL] [Abstract][Full Text] [Related]
10. Bcl-2 antagonists and cancer: from the clinic, back to the bench.
Esposti MD
Cell Death Dis; 2010 Apr; 1(4):e37. PubMed ID: 21364644
[No Abstract] [Full Text] [Related]
11. Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer.
Merino D; Lok SW; Visvader JE; Lindeman GJ
Oncogene; 2016 Apr; 35(15):1877-87. PubMed ID: 26257067
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and activity evaluation of broad-spectrum small-molecule inhibitors of anti-apoptotic Bcl-2 family proteins: characteristics of broad-spectrum protein binding and its effects on anti-tumor activity.
Zheng CH; Yang H; Zhang M; Lu SH; Shi D; Wang J; Chen XH; Ren XH; Liu J; Lv JG; Zhu J; Zhou YJ
Bioorg Med Chem Lett; 2012 Jan; 22(1):39-44. PubMed ID: 22172701
[TBL] [Abstract][Full Text] [Related]
13. Development of 3-phenyl-N-(2-(3-phenylureido)ethyl)-thiophene-2-sulfonamide compounds as inhibitors of antiapoptotic Bcl-2 family proteins.
Yang C; Chen S; Zhou M; Li Y; Li Y; Zhang Z; Liu Z; Ba Q; Li J; Wang H; Yan X; Ma D; Wang R
ChemMedChem; 2014 Jul; 9(7):1436-52. PubMed ID: 24782462
[TBL] [Abstract][Full Text] [Related]
14. Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy.
Azmi AS; Mohammad RM
J Cell Physiol; 2009 Jan; 218(1):13-21. PubMed ID: 18767026
[TBL] [Abstract][Full Text] [Related]
15. [Progress in small-molecule inhibitors of Bcl-2 family proteins].
Tang Y; Zhang DY; Wu XM
Yao Xue Xue Bao; 2008 Jul; 43(7):669-77. PubMed ID: 18819468
[TBL] [Abstract][Full Text] [Related]
16. BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis.
Miller LA; Goldstein NB; Johannes WU; Walton CH; Fujita M; Norris DA; Shellman YG
J Invest Dermatol; 2009 Apr; 129(4):964-71. PubMed ID: 18987671
[TBL] [Abstract][Full Text] [Related]
17. Bcl-2-regulated apoptosis: mechanism and therapeutic potential.
Adams JM; Cory S
Curr Opin Immunol; 2007 Oct; 19(5):488-96. PubMed ID: 17629468
[TBL] [Abstract][Full Text] [Related]
18. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S
Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795
[TBL] [Abstract][Full Text] [Related]
19. Conformational changes in Bcl-2 pro-survival proteins determine their capacity to bind ligands.
Lee EF; Czabotar PE; Yang H; Sleebs BE; Lessene G; Colman PM; Smith BJ; Fairlie WD
J Biol Chem; 2009 Oct; 284(44):30508-17. PubMed ID: 19726685
[TBL] [Abstract][Full Text] [Related]
20. Targeting the B-cell lymphoma/leukemia 2 family in cancer.
Davids MS; Letai A
J Clin Oncol; 2012 Sep; 30(25):3127-35. PubMed ID: 22649144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]